(Q47838940)

6 February 2018

title

Treatment of chronic hepatitis C in HIV/HCV-coinfection with interferon alpha-2b+ full-course vs. 16-week delayed ribavirin (English)

1 reference

6 February 2018

1 reference

1 reference

1 reference

Norbert Bräu

1

1 reference

6 February 2018

Maribel Rodriguez-Torres

2

1 reference

6 February 2018

Dale Prokupek

3

1 reference

6 February 2018

Maurizio Bonacini

4

1 reference

6 February 2018

Carol A Giffen

5

1 reference

6 February 2018

Jeffery J Smith

6

1 reference

6 February 2018

Kevin R Frost

7

1 reference

6 February 2018

Jay R Kostman

8

1 reference

6 February 2018

language of work or name

English

0 references

publication date

1 April 2004

1 reference

6 February 2018

published in

Hepatology

1 reference

6 February 2018

volume

39

1 reference

6 February 2018

issue

4

1 reference

6 February 2018

page(s)

989-998

1 reference

6 February 2018

Prevalence and determinants of antibodies to hepatitis C virus and markers for hepatitis B virus infection in patients with HIV infection in Aquitaine. Groupe d'Epidémiologie Clinique du SIDA en Aquitaine

cites work

1 reference

Ribavirin as therapy for chronic hepatitis C. A randomized, double-blind, placebo-controlled trial

21 January 2018

1 reference

Interferon-alpha in patients with asymptomatic human immunodeficiency virus (HIV) infection. A randomized, placebo-controlled trial

21 January 2018

1 reference

Increasing mortality due to end-stage liver disease in patients with human immunodeficiency virus infection

21 January 2018

1 reference

7 January 2021

Increasing impact of chronic viral hepatitis on hospital admissions and mortality among HIV-infected patients

1 reference

7 January 2021

Hepatitis C Virus prevalence among patients infected with Human Immunodeficiency Virus: a cross-sectional analysis of the US adult AIDS Clinical Trials Group

1 reference

7 January 2021

Human immunodeficiency virus infection modifies the natural history of chronic parenterally-acquired hepatitis C with an unusually rapid progression to cirrhosis

1 reference

7 January 2021

Mortality from liver cancer and liver disease in haemophilic men and boys in UK given blood products contaminated with hepatitis C. UK Haemophilia Centre Directors' Organisation

1 reference

7 January 2021

Liver fibrosis progression in human immunodeficiency virus and hepatitis C virus coinfected patients. The Multivirc Group

1 reference

7 January 2021

Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (I

1 reference

7 January 2021

Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group

1 reference

7 January 2021

The prevalence of hepatitis C virus infection in the United States, 1988 through 1994

1 reference

7 January 2021

Increased mitochondrial toxicity with ribavirin in HIV/HCV coinfection

1 reference

7 January 2021

Long-term efficacy of combination therapy with interferon-alpha 2b and ribavirin for severe chronic hepatitis C in HIV-infected patients

1 reference

7 January 2021

Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection

1 reference

7 January 2021

Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial

1 reference

7 January 2021

The toxicity of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex. A double-blind, placebo-controlled trial

1 reference

7 January 2021

Ribavirin treatment for patients with chronic hepatitis C: results of a placebo-controlled study

1 reference

7 January 2021

A randomized, controlled trial to determine whether continued ribavirin monotherapy in hepatitis C virus-infected patients who responded to interferon-ribavirin combination therapy will enhance sustained virologic response

1 reference

7 January 2021

Mechanism of action of ribavirin in the combination treatment of chronic HCV infection

1 reference

7 January 2021

Ribavirin antagonizes the effect of azidothymidine on HIV replication

1 reference

7 January 2021

Effect of ribavirin on zidovudine efficacy and toxicity in vitro: a concentration-dependent interaction

1 reference

7 January 2021

Effects of drugs on 2',3'-dideoxy-2',3'-didehydrothymidine phosphorylation in vitro

1 reference

7 January 2021

Interferon‐Ribavirin in Association with Stavudine Has No Impact on Plasma Human Immunodeficiency Virus (HIV) Type 1 Level in Patients Coinfected with HIV and Hepatitis C Virus: A CORIST‐ANRS HC1 Trial

1 reference

7 January 2021

Identifiers

DOI

10.1002/HEP.20107

1 reference

6 February 2018

1 reference

6 February 2018